vorbio.com (VOR) Quarterly EPS earnings growth

The quarterly EPS growth rate is recorded at 98.40, highlighting the protection of Vor Biopharma Inc. (VOR) business by unique patents in gene synthesis. However, a narrow focus on leukemia therapy creates significant binary risks for investors. Nevertheless, Vor Biopharma Inc. (VOR) maintains its status as an authoritative player in oncohematology thanks to breakthrough bone marrow protection methods.

VOR: Vor Biopharma Year-over-year earnings per share growth for the last twelve months 07/04/2022 - 11/14/2026

Vor Biopharma (VOR) - metric breakdowns and financial figures

- market value and analyst target forecast:

Price Chart vorbio.com|VOR - Average Forecast Price

- market capitalization details:

Market Capitalization Vor Biopharma, Inc.|VOR - Business Value

- balance sheet net asset value indicators:

Accounting Value per Share Vor Biopharma|VOR - Company Book Value|Market Value to Book Value Ratio vorbio.com|VOR - Company Assets

- debt and solvency information:

- earnings and valuation multiples information:

VOR - Company Net Income|Expected Profit Vor Biopharma Inc.|VOR - Market Cap to Net Income|Forward P/E Multiple Vor Biopharma Inc.|VOR - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Vor Bio Inc.|VOR - Operating profit EBITDA|Earnings per share for the last twelve months Vor Biopharma|VOR - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months vorbio.com|VOR - Net earnings per share growth this year|Earnings growth forecast for next year Vor Biopharma Inc.

- sales volume and revenue information:

VOR - Revenue and Sales Volume|Company Future Sales Volume Vor Bio|VOR - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Vor Biopharma, Inc.

Summary company analytics:Vor Bio - VOR

Professional managers utilize fundamental filters to identify the intrinsic value of assets. This indicator measures the rate of change in earnings per share, reflecting the balance between market supply and demand. For Vor Biopharma Inc. (VOR), success depends on the commercialization of leukemia therapy and contracts with oncology centers. The dynamics of these processes determine the final change in quarterly earnings per share. Analyzing this chart helps identify the exhaustion of growth drivers in a timely manner.

Direct competitors